Navigation Links
WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
Date:8/20/2009

SALT LAKE CITY, Aug. 20 /PRNewswire-FirstCall/ -- ("WorldHeart") (Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that it has received FDA conditional approval to begin a bridge-to-transplant (BTT) study of the Levacor Ventricular Assist Device (VAD) at ten US centers.

The company is required to provide some additional information to the FDA within 45 days, but the study is permitted to begin upon receipt of clinical center Institutional Review Board (IRB) approvals. WorldHeart has been working closely with a number of clinicians and clinical sites that are interested in participating in the Levacor Study.

Center expansion beyond the initial ten sites will be based upon a supplemental IDE application and subsequent FDA approval. Study enrollment will involve approximately 200 subjects, with an opportunity to demonstrate statistical significance through a planned interim analysis at approximately 150 subjects.

"We are extremely pleased to reach this key milestone in the development and clinical implementation of the Levacor VAD," said Mr. J. Alex Martin, WorldHeart's President and CEO. "We are also pleased that the clinical study has been assigned CMS category B2, which makes insurance reimbursement possible. Finally, we believe that our unique assist technology will provide life-saving potential for many heart-failure patients and further advance mechanical circulatory support therapy."

The Levacor VAD is the only bearingless, fully magnetically levitated, implantable centrifugal pump to enter clinical trials. The pump uses magnetic levitation to fully suspend the spinning rotor, its only moving part, inside a compact housing. As described by Mr. Jal S. Jassawalla, WorldHeart's Executive Vice President and Chief Technology Officer, "full magnetic levitation eliminates dependence on blood properties for rotor suspension, as well as wear within the pump. This design is expected to optimize blood compatibility by providing unobstructed clearances around the rotor, across a wide range of operation. We look forward to partnering with prominent clinicians at leading transplant centers to demonstrate Levacor safety and efficacy."

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs and the growth of its overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009.

    Contact Information:
    World Heart Corporation
    Mr. J. Alex Martin  (801) 303-4352
    Ms. Peggy Allman  (510) 563-4721
    www.worldheart.com


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... India , March 1, 2017 ... report "Neurovascular Devices/Interventional Neurology Market by Product (Embolic ... Flow Diversion Devices, Clot Retrievers), Pathology (Aneurysm, AVM) ... this report studies the neurovascular devices/interventional neurology market ... The market is expected to reach USD 2.62 ...
(Date:3/1/2017)... Mar 01, 2017 Research and Markets has announced the addition of the ... offering. ... country level, for instance North America (U.S., Canada ... France , Italy , U.K. and Spain ... India , Australia , South Korea ...
(Date:3/1/2017)... -- ... Research and Markets has announced the addition of the ... to their offering. The Global Human Papilloma Virus ... access to partnering deals and agreements entered into by the world,s ... partnering deals. The majority of deals are discovery or development stage ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... March 01, 2017 , ... Cognition Corporation ... a Human Factors Engineering (HFE) keynote speaker for its 2017 User Conference. , ... Cognition. “Human Factors is a dynamic part of product development, and our speaker ...
(Date:3/1/2017)... IL (PRWEB) , ... March 01, 2017 , ... First ... its latest funding round of $1.6 million. First Stop Health has raised total capital ... accelerate the company’s growth. , First Stop Health co-founder and CEO Patrick Spain (co-founder ...
(Date:3/1/2017)... ... March 01, 2017 , ... One of the most popular shows on ... the beloved character Toby being shocked back to life after suffering cardiac arrest on ... quickly back to his old self, ready to marry his best girl. In ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... ... the treatment of eating disorders, is pleased to announce the opening of residential ... facility. Starting this week, Aloria Health will accept adult clients for residential treatment. ...
(Date:3/1/2017)... , ... March 01, 2017 , ... ... Lung Cancer Conference® on April 8, 2017, in Sunny Isles Beach, Florida. The ... officer, Massachusetts General Physicians Organization, Boston, and Dr. Heather Wakelee, associate professor of ...
Breaking Medicine News(10 mins):